New consortium receives NIH grant to accelerate development of effective TB treatments

A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).